NCT05258331Unknown1 期
An Open-label, Dose-escalation, Phase 1 Trial to Investigate the Safety, Tolerability, and Efficacy After Single- and Multiple-dose Administration of CT303 in Patients With Moderate to Severe Plaque Psoriasis
适应症
干预措施
试验速览
- 阶段
- 1 期
- 入组人数
- 24
- 试验地点
- 3
- 主要终点
- TEAE (treatment-emergent adverse event) incidence rate
研究概览
简要总结
Investigate the Safety, Tolerability, Efficacy and pharmacodynamics properties of CT303 in patients with moderate to severe plaque psoriasis
详细描述
This study is a multi-center, open-label, dose-escalation and dose-finding phase 1 clinical trial. The primary purpose is to evaluate the safety and tolerability of CT303 and the secondary purpose is to evaluate the safety and efficacy of CT303 in patients with moderate to severe plaque psoriasis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥ 19 years old
- •Plaque psoriasis diagnosed before ≥ 6 months who did not show a sufficient response to one or more of the traditional systemic treatments or require change of treatment due to intolerance
- •Have moderate to severe plaque psoriasis as defined by PASI score ≥ 12, BSA ≥ 10% and sPGA score ≥ 3
- •Patients who have voluntarily decided to participate in the study and signed the informed consent form
排除标准
- •Guttate psoriasis, erythrodermic psoriasis, palmoplantar psoriasis, drug-induced psoriasis, and inverse psoriasis
- •History of treatment with cell therapy products including but not limited to mesenchymal stem cells
- •Have hypersensitivity, or medical history of clinically significant hypersensitivity, to the IP or its excipients
- •Current or history of cardiovascular diseases
- •Clinically significant hemorrhagic diseases, or gastrointestinal, respiratory, endocrinal, musculoskeletal, or neuropsychiatric disorders that are deemed by the investigator to be a potential threat to the safety of the subject due to study participation
- •Use of anticoagulants within 7 days prior to IP administration
- •Following treatment history for psoriasis
- •Use of topical therapy within the past 2 weeks
- •Use of phototherapy and/or systemic therapy within the past 4 weeks
- •Use of biologics within the past 4 to 24 weeks
- •Severe infection or other uncontrolled active infectious diseases requiring administration of systemic antibiotics, antivirals, etc. within 4 weeks prior to IP administration
- •Systemic or local inflammatory diseases requiring systemic anti-inflammatory treatment within 4 weeks prior to IP administration
- •Received or are scheduled to receive a live/live attenuated viral/bacterial vaccination within 12 weeks prior to IP administration (within 12 months for BCG vaccines)
- •Require administration of any prohibited concomitant medication specified in this protocol during participation in the study
- •QTc interval > 480 msec
- •Any of the following abnormalities or abnormal findings from laboratory tests:
- •AST or ALT > 3 times the upper limit of normal
- •Serum creatinine > 1.5 times the upper limit of normal
- •ANC < 1,500/μL, Hemoglobin < 10 g/dL, Platelet count < 100,000/μL
- •Hepatitis B or C infection or positive test for HIV at screening
- •History of malignant tumors within the last 5 years prior
- •Received or used any other IP or investigational device within 4 weeks prior to IP administration
- •Pregnant or breast-feeding women, or women of childbearing potential and men who do not agree to abstinence or use of effective methods of contraception from the time of obtaining informed consent and during the study
- •Patients who are deemed ineligible to participate in the study for other reasons by the investigator
研究组 & 干预措施
Single Arm
Experimental
CT303
干预措施: CT303 (Genetic)
结局指标
主要结局
TEAE (treatment-emergent adverse event) incidence rate
时间窗: Day 0 to Day 28
Evaluate safety through the incidence rate of TEAE (treatment-emergent adverse event) after CT303 administration
次要结局
未报告次要终点
研究者
研究点 (3)
Loading locations...
相似试验
撤回
1 期
Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With ARDSAcute Respiratory Distress SyndromeNCT05238532GC Cell Corporation
已完成
3 期
A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TBPulmonary TuberculosisNCT02333799Global Alliance for TB Drug Development109
已完成
1 期
First-in-human Study to Evaluate Safety, Tolerability and Pharmacokinetics of Various Doses of BCD-085 in Healthy SubjectsHealthyNCT02380287Biocad22
Unknown
1 期
Study of DP303c Administered Intravenously to Subjects With HER2-Positive in Advanced Solid TumorsNeoplasmsNCT04146610CSPC ZhongQi Pharmaceutical Technology Co., Ltd.30
终止
1 期
GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular CarcinomaAdvanced Hepatocellular CarcinomaNCT05352542jianming xu10